Rhenman & Partners Asset Management Ab Allogene Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $808,350 - $1.52 Million	255,000 Added 566.67%	300,000 $951,000
Q3 2023 Nov 09, 2023	SELL	$3.17 - $5.96 $808,350 - $1.52 Million	-255,000 Reduced 85.0%	45,000 $142,000
Q1 2023 May 11, 2023	SELL	$4.92 - $8.21 $196,800 - $328,400	-40,000 Reduced 11.76%	300,000 $1.48 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $103,200 - $172,800	-10,000 Reduced 2.86%	340,000 $3.5 Million
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $2.37 Million - $4.3 Million	350,000 New	350,000 $3.99 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.